Transplant characteristics
| Characteristic . | Total N = 240 . |
|---|---|
| Age at HCT, median (range), y | 5.0 (0.3-28.1) |
| HCT (y), median, n (%) | 2013 |
| 1996-2000 | 9 (3.8) |
| 2001-2005 | 15 (6.3) |
| 2006-2010 | 43 (17.9) |
| 2011-2015 | 114 (47.5) |
| 2016-2018 | 59 (24.6) |
| Donor type, n (%) | |
| MSD/MRD | 60 (25.0) |
| MUD | 118 (49.2) |
| MMRD | 22 (9.2) |
| MMUD | 40 (16.7) |
| Donor gender, n (%) | |
| Female | 100 (41.7) |
| Male | 140 (58.3) |
| Stem cell source, n (%) | |
| Bone marrow | 130 (54.2) |
| Peripheral blood stem cells | 71 (29.6) |
| UCB | 36 (15.0) |
| Cord blood + bone marrow | 3 (1.3) |
| T-cell depletion, n (%) | |
| CD34+ selection | 9 (3.8) |
| TCRαβ+/CD19+ cell depletion | 3 (1.3) |
| CD3+/CD19+ cell depletion | 1 (0.4) |
| Conditioning regimen, n (%) | |
| Traditional Bu/Cy | 62 (25.8) |
| Bu/Cy | 33 (14) |
| Bu/Cy/Flu | 25 (10) |
| Bu/Cy/AraC or etoposide | 4 (1.7) |
| Alternative regimens | 178 (74.2) |
| Bu/Flu | 78 (32.5) |
| Bu/Flu/thiotepa | 5 (2.1) |
| Bu/TBI | 42 (17.5) |
| Bu | 5 (2.1) |
| Flu/Mel | 16 (6.7) |
| Flu/Mel/thiotepa | 11 (4.6) |
| Flu/Mel/Cy | 1 (0.4) |
| Flu/Mel/TBI | 1 (0.4) |
| Flu/Treo | 7 (3.0) |
| Flu/Treo/TBI | 1 (0.4) |
| Flu/Cy | 3 (1.3) |
| Flu/Cy/TBI | 2 (0.8) |
| Flu/TBI | 5 (2.1) |
| Flu/thiotepa | 1 (0.4) |
| Serotherapy, n (%) | |
| ATG | 105 (43.8) |
| Alemtuzumab | 115 (47.9) |
| None | 20 (8.3) |
| GVHD prophylaxis, n (%) | |
| CNI + MMF ± other | 80 (33.3) |
| CNI + MTX ± other | 52 (21.7) |
| CNI ± other | 48 (20.0) |
| PTCy ± other | 12 (5.0) |
| Sirolimus | 36 (15.0) |
| Other | 5 (2.1) |
| None | 7 (2.9) |
| Characteristic . | Total N = 240 . |
|---|---|
| Age at HCT, median (range), y | 5.0 (0.3-28.1) |
| HCT (y), median, n (%) | 2013 |
| 1996-2000 | 9 (3.8) |
| 2001-2005 | 15 (6.3) |
| 2006-2010 | 43 (17.9) |
| 2011-2015 | 114 (47.5) |
| 2016-2018 | 59 (24.6) |
| Donor type, n (%) | |
| MSD/MRD | 60 (25.0) |
| MUD | 118 (49.2) |
| MMRD | 22 (9.2) |
| MMUD | 40 (16.7) |
| Donor gender, n (%) | |
| Female | 100 (41.7) |
| Male | 140 (58.3) |
| Stem cell source, n (%) | |
| Bone marrow | 130 (54.2) |
| Peripheral blood stem cells | 71 (29.6) |
| UCB | 36 (15.0) |
| Cord blood + bone marrow | 3 (1.3) |
| T-cell depletion, n (%) | |
| CD34+ selection | 9 (3.8) |
| TCRαβ+/CD19+ cell depletion | 3 (1.3) |
| CD3+/CD19+ cell depletion | 1 (0.4) |
| Conditioning regimen, n (%) | |
| Traditional Bu/Cy | 62 (25.8) |
| Bu/Cy | 33 (14) |
| Bu/Cy/Flu | 25 (10) |
| Bu/Cy/AraC or etoposide | 4 (1.7) |
| Alternative regimens | 178 (74.2) |
| Bu/Flu | 78 (32.5) |
| Bu/Flu/thiotepa | 5 (2.1) |
| Bu/TBI | 42 (17.5) |
| Bu | 5 (2.1) |
| Flu/Mel | 16 (6.7) |
| Flu/Mel/thiotepa | 11 (4.6) |
| Flu/Mel/Cy | 1 (0.4) |
| Flu/Mel/TBI | 1 (0.4) |
| Flu/Treo | 7 (3.0) |
| Flu/Treo/TBI | 1 (0.4) |
| Flu/Cy | 3 (1.3) |
| Flu/Cy/TBI | 2 (0.8) |
| Flu/TBI | 5 (2.1) |
| Flu/thiotepa | 1 (0.4) |
| Serotherapy, n (%) | |
| ATG | 105 (43.8) |
| Alemtuzumab | 115 (47.9) |
| None | 20 (8.3) |
| GVHD prophylaxis, n (%) | |
| CNI + MMF ± other | 80 (33.3) |
| CNI + MTX ± other | 52 (21.7) |
| CNI ± other | 48 (20.0) |
| PTCy ± other | 12 (5.0) |
| Sirolimus | 36 (15.0) |
| Other | 5 (2.1) |
| None | 7 (2.9) |
Matching of MMRD and MMUD were as follows: MMRD: 3 of 8 (n = 2), 4 of 8 (n = 5), 5 of 6 (n = 1), 5 of 8 (n = 6), 6 of 8 (n = 1), 7 of 8 (n = 7) and MMUD: 4 of 6 (n = 2), 5 of 6 (n = 4), 5 of 8 (n = 4), 6 of 8 (n = 8), 7 of 8 (n = 22)
AraC, cytarabine; Bu, busulfan; CNI, calcineurin inhibitor; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; PTCy, posttransplant cyclophosphamide; RIC/RTC, reduced intensity conditioning/reduced toxicity conditioning; TBI, total body irradiation; Treo, treosulfan.